Stockwatch: Riding the M&A rollercoaster
This article was originally published in Scrip
Executive Summary
An important dynamic currently driving the biopharmaceutical space is the replacement of lost product revenue at pharmaceutical companies through merger and acquisition (M&A) transactions biotechs with promising pipelines. However, the hoped for renewal is not always a smooth path and is more often more akin to riding a rollercoaster.